Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 38, Issue 12, Pages 2186-2197Publisher
SPRINGER
DOI: 10.1007/s00259-011-1907-9
Keywords
Positron emission tomography; Angiogenesis; [F-18]Fluciclatide; Kinetic modelling; RGD; Integrin alpha(nu)beta(3/5)
Funding
- MRC [MC_U120085814, MC_U120081322] Funding Source: UKRI
- Cancer Research UK [10337] Funding Source: researchfish
- Medical Research Council [MC_U120081322, MC_U120085814] Funding Source: researchfish
- National Institute for Health Research [NIHR/CS/009/009] Funding Source: researchfish
- National Institutes of Health Research (NIHR) [NIHR/CS/009/009] Funding Source: National Institutes of Health Research (NIHR)
- Cancer Research UK [10337] Funding Source: Medline
- Medical Research Council [MC_U120081322, MC_U120085814] Funding Source: Medline
- Department of Health [NIHR/CS/009/009] Funding Source: Medline
Ask authors/readers for more resources
Purpose The purpose of the study was to estimate the receptor-ligand binding of an arginine-glycine-aspartic acid (RGD) peptide in somatic tumours. To this aim, we employed dynamic positron emission tomography (PET) data obtained from breast cancer patients with metastases, studied with the alpha(nu)beta(3/5) integrin receptor radioligand [F-18] fluciclatide. Methods First, compartmental modelling and spectral analysis with arterial input function were performed at the region of interest (ROI) level in healthy lung and liver, and in lung and liver metastases; compartmental modelling was also carried out at the pixel level. The selection of the most appropriate indexes for tumour/healthy tissue differentiation and for estimation of specific binding was then assessed. Results The two-tissue reversible model emerged as the best according to the Akaike Information Criterion. Spectral analysis confirmed the reversibility of tracer kinetics. Values of kinetic parameters, estimated as mean from parametric maps, correlated well with those computed from ROI analysis. The volume of distribution VT was on average higher in lung metastases than in the healthy lung, but lower in liver metastases than in the healthy liver. In agreement with the expected higher alpha(nu)beta(3/5) expression in pathology, k(3) and k(3)/k(4) were both remarkably higher in metastases, which makes them more suitable than VT for tumour/healthy tissue differentiation. The ratio k(3)/k(4), in particular, appeared a reasonable measure of specific binding. Conclusion Besides establishing the best quantitative approaches for the analysis of [F-18]fluciclatide data, this study indicated that the k(3)/k(4) ratio is a reasonable measure of specific binding, suggesting that this index can be used to estimate alpha(nu)beta(3/5) receptor expression in oncology, although further studies are necessary to validate this hypothesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available